Details of the Drug Formulations

General Information of Drug (ID: DMTL94F)

Drug Name
Maraviroc Drug Info
Synonyms
376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [1]
Therapeutic Class
Anti-HIV Agents
Cross-matching ID
PubChem CID
3002977
ChEBI ID
CHEBI:63608
CAS Number
376348-65-1
TTD ID
D0NR6S
VARIDT ID
DR00730
ACDINA ID
D00384

Full List of Drug Formulations Containing This Drug

Maraviroc 150 mg tablet
Company Formulation ID FDA Description
Pfizer Laboratories F12701 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Polyethylene glycol; Sodium starch glycolate type a potato
ViiV Healthcare Company F12699 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Hydrogenated soybean lecithin; Polyethylene glycols; Sodium starch glycolate type a potato
RemedyRepack F12700 Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Polyvinyl alcohol; Aluminum oxide; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Hydrogenated soybean lecithin; Polyethylene glycols; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Maraviroc 300 mg tablet
Company Formulation ID FDA Description
Pfizer Laboratories F12706 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Polyethylene glycol; Sodium starch glycolate type a potato
Physicians Total Care F12707 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Polyethylene glycols; Sodium starch glycolate type a potato
ViiV Healthcare Company F12703 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Hydrogenated soybean lecithin; Polyethylene glycols; Sodium starch glycolate type a potato
A-S Medication Solutions F12704 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Aluminum oxide; Hydrogenated soybean lecithin; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified; Sodium starch glycolate type a potato
A-S Medication Solutions F12705 Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Polyvinyl alcohol; Aluminum oxide; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Hydrogenated soybean lecithin; Polyethylene glycols; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Maraviroc 25 mg tablet
Company Formulation ID FDA Description
ViiV Healthcare Company F12702 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Hydrogenated soybean lecithin; Polyethylene glycols; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Maraviroc 75 mg tablet
Company Formulation ID FDA Description
ViiV Healthcare Company F12708 Fd&c blue no. 2; Magnesium stearate; Anhydrous dibasic calcium phosphate; Talc; Titanium dioxide; Polyvinyl alcohol; Aluminum oxide; Cellulose, microcrystalline; Hydrogenated soybean lecithin; Polyethylene glycols; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).